Actavis manufacturing woes spur US recall
This article was originally published in Scrip
Executive Summary
Iceland-based generics maker Actavishas recalled from the US market all drug products made at the company's Little Falls, New Jersey solid oral dose facility owing to good manufacturing practice deficiencies. The recall impacts 66 products, many with multiple formulations, and involves a facility with a history of compliance problems. The affected medicines include some that have not received formal FDA approval.